Advertisement

Topics

Astex Pharmaceuticals Celebrates as Cancer Drug Receives Marketing Approval in Europe

12:00 EDT 24 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Further Milestone Payment Under Novartis Collaboration as Kisqali® (ribociclib) Receives Approval in Europe as a First-Line Treatment for HR+/HER2- locally Advanced or Metastatic Breast Cancer with an Aromatase Inhibitor ...

Other Sources for this Article

Astex Pharmaceuticals
Jeremy Carmichael, +44(0)1223 226289
Mobile: +44 (0)7786 738066
VP Corporate Development
Head of Business Development
jeremy.carmichael@astx.com

NEXT ARTICLE

More From BioPortfolio on "Astex Pharmaceuticals Celebrates as Cancer Drug Receives Marketing Approval in Europe"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...